Patient value: its nature, measurement, and role in real world evidence studies and outcomes-based reimbursement

被引:15
|
作者
McKenna, Stephen P. [1 ,2 ]
Wilburn, Jeanette [1 ]
机构
[1] Galen Res Ltd, B1 Chorlton Mill,3 Cambridge St, Manchester M1 5BY, Lancs, England
[2] Univ Manchester, Sch Hlth Sci, Manchester, Lancs, England
关键词
Health-related quality-of-life; health service evaluation; needs-based quality-of-life; outcomes-based reimbursement; patient reported outcome measures; patient value; real world evidence; QUALITY-OF-LIFE; HEALTH; PSORIASIS; PSORIQOL; SCORES;
D O I
10.1080/13696998.2018.1450260
中图分类号
F [经济];
学科分类号
02 ;
摘要
The assessment of patient value is fundamental to clinical trials, real world evidence studies, and outcomes-based reimbursement schemes. Measures of health-related quality-of-life (HRQoL) are widely used in health research. Such measures are effective in determining the presence or absence of symptoms and functional ability. However, HRQoL measures were not intended, nor designed, to determine the value to patients of alternative health states. Functions have no intrinsic value-they are a means to fulfil human needs. However, needs can be met in a variety of ways, for example by adopting different functions or by the provision of social services. It is possible to analyze all functions in terms of the needs they satisfy. A needs model has been applied in health research since the 1990s. It is concerned with the extent to which human needs are fulfilled in the presence of disease and its treatment. It is argued that this is the major concern of the patient. Needs-based measures are patient-centric and produce a valid unidimensional index of outcome. Consequently, they provide a direct means of measuring patient value. This approach provides the possibility of evaluating health services in terms of the value they provide to consumers and payers. It also has a role to play in real-world evidence studies and outcomes-based reimbursement. It is recommended that greater attention is given in future to the development of patient-reported outcome measures that provide direct assessments of patient value.
引用
收藏
页码:474 / 480
页数:7
相关论文
共 50 条
  • [41] Evidence-based medicine between Phase III Studies and "real world"-data
    Moeller, Hans-Juergen
    PSYCHOPHARMAKOTHERAPIE, 2011, 18 (01): : 1 - 1
  • [42] STRENGTHENING THE PATIENT VOICE IN HEALTH OUTCOME MEASUREMENT IN REAL-WORLD DATA IN EUROPE - THE HEALTH OUTCOMES OBSERVATORY
    Stamm, T.
    Andrews, M.
    Benard, A. H. M.
    Cossio, Y.
    Delnoij, D.
    Kalra, D.
    Koppert, L.
    Long, P.
    Mosor, E.
    Otto, L.
    Rose, M.
    Kristensen, Scholer J.
    Thwaites, R.
    Styliadou, M.
    VALUE IN HEALTH, 2022, 25 (12) : S472 - S472
  • [43] THE ROLE OF ELECTRONIC HEALTH RECORDS IN THE ADVANCEMENT OF REAL WORLD EVIDENCE BASED RESEARCH IN ONCOLOGY
    Mazumder, D.
    ARgentinis, E.
    Dhangar, I
    VALUE IN HEALTH, 2020, 23 : S384 - S384
  • [44] A Call for Appropriate Evidence and Outcomes-Based Use and Measurement of Anticoagulation for Atrial Fibrillation: Moving the Population Towards Improved Health Via Multiple Stakeholders
    Kountz, David S.
    Shaya, Fadia T.
    Gradman, Alan H.
    Puckrein, Gary A.
    Kim, Michael H.
    Wilbanks, Jennifer
    Stevenson, James G.
    Larsen, David L.
    Wysong, Michael
    Chirikov, Viktor
    Pan, Wayne T.
    Xu, Liou
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (11): : 1034 - 1038
  • [45] Value-Based Health Care for Chronic Care: Aligning Outcomes Measurement with the Patient Perspective
    Ebbevi, David
    Forsberg, Helena Hvitfeldt
    Essen, Anna
    Ernestam, Sofia
    QUALITY MANAGEMENT IN HEALTH CARE, 2016, 25 (04) : 203 - 212
  • [46] REAL WORLD EVIDENCE OF THE EFFECT OF PERIPHERAL ARTERIAL DISEASE (PAD) ON PATIENT HEALTH OUTCOMES AND COSTS IN AUSTRALIA.
    Hegadekatti, N.
    Strachan, L.
    VALUE IN HEALTH, 2019, 22 : S570 - S570
  • [47] Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
    Lau, Catherine
    Dranitsaris, George
    CURRENT ONCOLOGY, 2022, 29 (11) : 8031 - 8042
  • [48] Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
    Lau, Catherine Y.
    Rawson, Nigel S. B.
    CURRENT ONCOLOGY, 2024, 31 (09) : 5599 - 5607
  • [49] Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies?
    Devillier, Philippe
    Demoly, Pascal
    Molimard, Mathieu
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (05) : 445 - 452
  • [50] INFORMING THE DESIGN OF VALUE-BASED CONTRACTS: USE OF RANDOMIZED TRIAL AND REAL-WORLD EVIDENCE
    Patrick, A.
    Gorsuch, T.
    Rassen, J.
    VALUE IN HEALTH, 2019, 22 : S121 - S121